- Preview Available
- Scholarly Journal
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
Blood Cancer Journal; London Vol. 15, Iss. 1, (Dec 2025): 109.
DOI:10.1038/s41408-025-01296-8
This is a limited preview of the full PDF
Try and log in through your library or institution to see if they have access.